NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2006
Business Overview: NAI provides private label contract manufacturing services for vitamins, minerals, and nutritional supplements. It also develops and markets its own branded products. Operations include facilities in California (USA) and Switzerland (NAIE). On December 5, 2005, NAI acquired Real Health Laboratories, Inc. (RHL), a direct marketer of branded nutritional supplements, creating a second business segment.

Key Financial Metrics

Revenue by Segment (2006): Private Label Contract Manufacturing ($85.3M, 86.0%); Direct-to-Consumer ($8.1M, 8.2%); RHL ($5.7M, 5.8%).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8% to $99.1 million, driven by the acquisition of RHL and a new relationship with Arbonne International (10% of sales). Sales to the largest customer, NSA International, Inc., grew slightly, while sales to Mannatech, Inc. declined due to a shift to lower-priced products.
• Profitability: Gross margin improved by 2.5 percentage points to 22.6%, attributed to the RHL acquisition and a favorable shift in sales mix (less powder, more capsules/tablets). Operating income rose 22% to $4.6 million.
• Debt Increase: Total debt surged from $3.8 million to $15.9 million. This was primarily due to a $3.8 million term loan to fund the RHL acquisition and increased utilization of the working capital line of credit ($9.6 million outstanding) to fund inventory for new customer orders.
• Cash Flow: Net cash used in operating activities was $3.8 million (compared to $2.5 million provided in 2005), largely due to increases in accounts receivable and inventory.

Guidance, Outlook, and Risks

Outlook: Management expects to continue the long-term trend of annual revenue growth. Strategic focus remains on leveraging certified facilities, expanding branded products through RHL, and improving operational efficiencies. Quarterly revenue fluctuations are anticipated due to customer order timing.

Key Risks:

• Customer Concentration: The top three customers (NSA International, Mannatech, and Arbonne) accounted for approximately 77% of net sales in 2006. The loss of a major customer would materially affect results.
• Acquisition Integration: Risks associated with integrating RHL, including potential impairment of goodwill and failure to achieve cost synergies.
• Liquidity: While the company has a $12.0 million credit line, it relies on cash flows and borrowings to meet working capital needs. Failure to maintain loan covenants could restrict access to credit.
• Regulatory: Operations are subject to extensive FDA and international regulations regarding product claims, labeling, and manufacturing practices.

Unusual Items: A $120,000 settlement was paid to Novogen Research regarding a patent infringement claim. The company also incurred $1.0 million in revenue reductions related to a one-time rebate program by RHL.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with NSA International (38% of sales) and Mannatech (29% of sales).
• Debt Covenants: Review the amended credit facility terms, specifically the fixed charge coverage ratio and total liabilities to tangible net worth ratios, to ensure compliance.
• Inventory Valuation: Assess the $3.7 million inventory investment for a new customer where delivery dates are being rescheduled; verify the likelihood of a write-down.
• RHL Integration: Monitor the realization of cost savings and revenue synergies from the RHL acquisition against the $7.2 million goodwill recorded.
• Foreign Currency Exposure: Evaluate the effectiveness of hedging strategies given the company's exposure to the Euro and Swiss Franc.